Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103996 | 0.89 | OPRK1 (0.47) | HRH3OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9104652 | 0.85 | KDM2B (0.44) | KDM2BLSS | |
| SCHEMBL9104659 | 0.85 | KDM2B (0.44) | KDM2BLSS | |
| SCHEMBL9106444 | 0.84 | HRH3 (0.51) | HRH3OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9102643 | 0.83 | HRH3 (0.50) | HRH3OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9102579 | 0.83 | HRH3 (0.50) | HRH3OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9101596 | 0.83 | HRH3 (0.50) | HRH3OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9102562 | 0.83 | HRH3 (0.50) | HRH3OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9101608 | 0.83 | HRH3 (0.50) | HRH3OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9104502 | 0.82 | HRH3 (0.44) | HRH3OPRK1CCR5OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | HRH3 942/4885OPRK1 398/4885CCR5 3686/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | HRH3 942/4885OPRK1 398/4885CCR5 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.